UNSPSC 51181627: Liothyronine sodium

This classification denotes a generic primary tumor tnm finding with the molecular formula C15H11I3NO4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCA9VV7D2N, chemically known as l-tyrosine, o-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt, but more generally known as liothyronine sodium, which bears US NIH Compound Identifier 5919. European Medicines Agency schedules liothyronine sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08527MIG.

Most nations, for tariff purposes, schedule liothyronine sodium under HS 29374000. Liothyronine sodium bears US NLM identifiers UMLS ID C0546882 and NCI Concept Code C2581. SMILES: C1CC(C(CC1OC2C(CC(CC2I)C[C@@H](C(=O)[O-])N)I)I)O.[NA+].

UNSPSC 51181627 Liothyronine sodium is a Commodity code covering the procurement of this specific thyroid hormone replacement medication by state and local health systems, correctional facilities, and public health agencies. State and local governments acquire liothyronine sodium through cooperative purchasing vehicles and direct pharmaceutical supply agreements, typically as part of broader multi-source generic pharmaceutical contracts that bundle dozens or hundreds of medications under centralized pricing and distribution frameworks. Issuing bodies include state departments of health and administration, county public health departments, and regional health systems that participate in multistate cooperative purchasing alliances. The work involves manufacturers or authorized distributors providing pharmaceutical-grade liothyronine sodium with verified National Drug Codes, specific dosage forms and strengths, compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and reliable supply through authorized wholesaler networks with chargeback and EDI capability.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities in Minnesota, Oregon, and other alliance member jurisdictions. Proposals were due March 26, 2026, with awarded vendors to supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with contract effectiveness July 1, 2026. Evaluation weighting favors price competitiveness at 75 percent, with the remaining 25 percent split across fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must maintain $5 million commercial general liability insurance, $2 million network security and privacy liability coverage, and $2 million professional liability insurance, and comply with performance penalties ranging from $200 to $1,500 per violation.